TITLE

Industry waits for fallout from Cabilly

AUTHOR(S)
Waltz, Emily
PUB. DATE
July 2007
SOURCE
Nature Biotechnology;Jul2007, Vol. 25 Issue 7, p699
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the move of Genentech Inc. to appeal on the U.S. Patent and Trademark Office's decision in rejecting its widely licensed monoclonal antibody patent, called Cabilly II. It is noted that Cabilly is one of the most ubiquitous patents in biotechnology. The author pointed out that the momentum against Cabilly II is encouraging licensees and potential licensees to consider ways to avoid royalty payments.
ACCESSION #
25681907

 

Related Articles

  • Patent Office rejects Genentech’s Cabilly claims. Harrison, Charlotte // Nature Reviews Drug Discovery;Apr2007, Vol. 6 Issue 4, p262 

    The article reports the Genentech's Cabilly claim is rejected by US Patent and Trademark office. The patent covers the monoclonal antibodies production from recombinant DNA technology and was issued to Genentech in 2001. The examination of the proceedings related to the claims is presented....

  • GENENTECH GRANTED PATENT FOR FUNDAMENTAL ANTIBODY TECHNOLOGY.  // Biotech Business;Feb2002, Vol. 15 Issue 2, p7 

    No abstract available.

  • Four rebuffs for Cabilly. E. W. // Nature Biotechnology;Apr2008, Vol. 26 Issue 4, p362 

    The article reports on the rejection of Genentech Inc.'s licensed recombinant antibody patent, Cabilly 2, by the U.S. Patent and Trademark Office's (USPTO) for the fourth time on February 2008. USPTO argued that Cabilly 2 is merely a variation of several earlier patents. However, it notes that...

  • Applications Update.  // PharmaWatch: Biotechnology;Aug2010, Vol. 9 Issue 8, p9 

    The article offers information on the applications submitted to the U.S. Food and Drug Administration (FDA) and the U.S. Patent and Trade Office (USPTO). Genentech Inc. submitted its biologics license application to the FDA for trastuzumab-DM1, a cancer antigen used by the company in its...

  • Legislative Background.  // Congressional Digest;Dec96, Vol. 75 Issue 12, p299 

    Provides information about a number of bills introduced during the 104th Congress to alter the organization of the US Patent and Trademark Office ad reform some of its procedures. House legislation; Senate legislation; Other intellectual property rights bills.

  • Should the Patent and Trademark Office Be a Government Corporation? PRO. Lehman, Bruce A. // Congressional Digest;Dec96, Vol. 75 Issue 12, p300 

    Argues for the reorganization of the US Patent and Trademark Office (PTO) as a wholly owned government corporation. Concepts that underlie the US Department of Commerce's approach to the reorganization of the PTO; Structure of the actual patent and trademark examining organization.

  • Should the Patent and Trademark Office Be a Government Corporation? CON. Rohrabacher, Dana // Congressional Digest;Dec96, Vol. 75 Issue 12, p301 

    Argues against the reorganization of the US Patent and Trademark Office (PTO) as a wholly owned government corporation. Protection of private property rights as an inherent governmental function; Privatization of certain government functions; Removal of civil service status for the employees of...

  • Should the Patent and Trademark Office Be a Government Corporation? CON. Hunter, Duncan // Congressional Digest;Dec96, Vol. 75 Issue 12, p305 

    Argues against the reorganization of the US Patent and Trademark Office (PTO) as a wholly owned government corporation. Importance of the patent system; Basic reason for the existence of the PTO; Pantent Office as a core Federal function; Customers of the PTO.

  • More trouble at the US patent office. Fox, Barry // New Scientist;4/23/94, Vol. 142 Issue 1922, p21 

    Reports on United States Patent and Trademark Office's revocation of a basic patent on video tape recording technology it had granted to Eastman Kodak Company. Freeze on patent infringement action filed by Kodak against Sony Corp.; Basis of Kodak's claim; Sony's prior art documents.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics